



Sitravatinib (MGCD516)


Cat. No.:	OB0225WX-2765
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	5 mg; 25 mg; 100 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	Sitravatinib is a novel small molecule designed to inhibit a broad spectrum of receptor tyrosine kinases (RTKs), including c-Kit, PDGFR alpha/beta, c-Met, and Axl.
Synonym	MG-516; 1123837-84-2; MGCD516; MG-516; MGCD-516; Sitravatinib (MGCD516); MG-91516; 1-N'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; MGCD 516; 1,1-Cyclopropanedicarboxamide, N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)-2-pyridinyl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-N'-(4-fluorophenyl)-; 1,1-Cyclopropanedicarboxamide, N-[3-fluoro-4-[[2-[5-[(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl)-N'-(4-fluorophenyl)-; N-(3-Fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
CAS No.	1123837-84-2
Compound CID	25212148
Formula	C ₃₃ H ₂₉ F ₂ N ₅ O ₄ S
Formula Weight	629.68

Specification



IUPAC Name	1- <i>N'</i> -[3-Fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1- <i>N</i> -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
InChI	InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)
InChI Key	WLAVZAAODLTUSW-UHFFFAOYSA-N
SMILES string	<chem>COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F</chem>
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	Sitratatinib is utilized in advanced oncology research as a multi-targeted tyrosine kinase inhibitor to investigate the simultaneous inhibition of VEGFR, TAM, and Split family receptors in the tumor microenvironment.

Library Information

Target	Axl; c-Kit; Ephrin receptor; Trk receptor; VEGFR
Receptor	Axl; c-Kit; Ephrin receptor; Trk receptor; VEGFR
Pathways	Protein tyrosine kinase
Plate Number	L6700-10
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	100 mg/mL; 158.81 mM
Ethanol Max Solubility	100 mg/mL
ALogP	5.029
HBA_Count	6
HBD_Count	3
Rotatable Bond	12